Hemab Therapeutics (NASDAQ:COAG) Releases Earnings Results

Hemab Therapeutics (NASDAQ:COAG) posted its quarterly earnings data on Thursday. The company reported ($23.98) earnings per share (EPS) for the quarter, Zacks reports.

Hemab Therapeutics Stock Up 4.0%

Hemab Therapeutics stock opened at $26.47 on Thursday. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $36.61.

Insider Activity at Hemab Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 2,675,000 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were acquired at an average price of $18.00 per share, with a total value of $48,150,000.00. Following the completion of the transaction, the director owned 6,149,096 shares of the company’s stock, valued at $110,683,728. The trade was a 77.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired a total of 2,898,074 shares of company stock valued at $53,650,008 in the last three months.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.